Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: Continuous glucose telemetry analysis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Iuchi, Hiroyuki ^a   Sakamoto, Masaya ^a   Matsutani, Daisuke ^a   Suzuki, Hirofumi ^a   Kayama, Yosuke ^a   Takeda, Norihiko ^b   Minamisawa, Susumu ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSIDE; IPRAGLIFLOZIN; THIOPHENE DERIVATIVE;

ANALYSIS; ANIMAL; BLOOD; BODY TEMPERATURE; CHEMICALLY INDUCED; CIRCADIAN RHYTHM; DRINKING; DRUG EFFECT; EATING; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSURIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGY; RAT; URINE; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; BODY TEMPERATURE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRINKING; EATING; ENERGY METABOLISM; GLUCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, WISTAR; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; THIOPHENES;

EID: 85029842730     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-12106-y     Document Type: Article

References (37)

1. Ogurtsova, K. et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice 128, 40-50 (2017).
2. Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 91 million participants. Lancet 377, 557-567 (2011).
3. American Diabetes Association. 7. Obesity Management for the Treatment of Type 2 Diabetes. Diabetes Care 40, S57-S63 (2017).
4. Carls, G., Huynh, J., Tuttle, E., Yee, J. & Edelman, S. V. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Therapy 8, 863-873 (2017).
5. Chao, E. C. & Henry, R. R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9, 551-559 (2010).
6. Kashiwagi, A., Kazuta, K., Yoshida, S. & Nagase, I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest 5, 382-391 (2014).
7. Iemitsu, K. et al. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. J Clin Med Res 8, 373-378 (2016).
8. Ferrannini, G. et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38, 1730-1735 (2015).
9. Devenny, J. J. et al. Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats. Obesity (Silver Spring) 20, 1645-1652 (2012).
10. PhD, D. K. D. H. et al. Obesity 3 Quantification of the effect of energy imbalance on bodyweight. The Lancet 378, 826-837 (2011).
11. Shah, J. H., Wongsurawat, N., Aran, P. P., Motto, G. S. & Bowser, E. N. A method for studying acute insulin secretion and glucose tolerance in unanesthetized and unrestrained rats. The effect of mild stress on carbohydrate metabolism. Diabetes 26, 1-6 (1977).
12. Brockway, R. et al. Fully Implantable Arterial Blood Glucose Device for Metabolic Research Applications in Rats for Two Months. Journal of Diabetes Science and Technology 9, 771-781 (2015).
13. Atageldiyeva, K. et al. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice. PLoS ONE 11, e0157672-17 (2016).
14. Chiba, Y. et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS ONE 11, e0150756-13 (2016).
15. Sullivan, M. A., Harcourt, B. E., Xu, P., Forbes, J. M. & Gilbert, R. G. Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics Curr Drug Targets 16, 1088-1093 (2015).
16. Zhang, T. M., Ostenson, C. G. & Malaisse, W. J. Glycogen synthase, glycogen phosphorylase and alpha-amylase activity in homogenates of islets of GK rats: comparison with hepatic and pancreatic extracts. Cell Biochem. Funct. 12, 185-189 (1994).
17. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509-514 (2014).
18. Ferrannini, E. et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 65, 1190-1195 (2016).
19. Xu, L. et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine 20, 137-149 (2017).
20. Naznin, F. et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. European Journal of Pharmacology 794, 37-44 (2017).
21. Yokono, M. et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat dietinduced obese rats. European Journal of Pharmacology 727, 66-74 (2014).
22. Liang, Y. et al. Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE 7, e30555-7 (2012).
23. Choi, M.-S. et al. High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodellingand inflammation-related genes. Br. J. Nutr. 113, 867-877 (2015).
24. Iwata, K. et al. Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats. J Physiol Sci 61, 103-113 (2011).
25. Carneiro, L. et al. Evidence for hypothalamic ketone body sensing: impact on food intake and peripheral metabolic responses in mice. AJP: Endocrinology and Metabolism 310, E103-15 (2016).
26. Ferrannini, E. et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 65, 1190-1195 (2016).
27. Hernandez, L. & Briese, E. Analysis of diabetic hyperphagia and polydipsia. Physiol. Behav. 9, 741-746 (1972).
28. Sahu, A. et al. Neuropeptide Y release from the paraventricular nucleus increases in association with hyperphagia in streptozotocininduced diabetic rats. Endocrinology 131, 2979-2985 (1992).
29. Maekawa, F. et al. Young Adult-Specific Hyperphagia in Diabetic Goto-Kakizaki Rats is Associated with Leptin Resistance and Elevation of Neuropeptide Y mRNA in the Arcuate Nucleus. J Neuroendocrinol 18, 748-756 (2006).
30. Bizot-Espiard, J. G. et al. Diurnal rhythms in plasma glucose, insulin, growth hormone and melatonin levels in fasted and hyperglycaemic rats. Diabetes & Metabolism 24, 235-240 (1998).
31. Torimoto, K., Okada, Y., Mori, H. & Tanaka, Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 12, 1-1 (2013).
32. Jun, J. E. et al. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol 14, 70 (2015).
33. Moreira, P. I., Santos, M. S., Moreno, A. M., Seiça, R. & Oliveira, C. R. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes 52, 1449-1456 (2003).
34. Yabe, D. et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 19, 739-743 (2017).
35. Brown, C. M., Dulloo, A. G. & Montani, J.-P. Water-Induced Thermogenesis Reconsidered: The Effects of Osmolality and Water Temperature on Energy Expenditure after Drinking. The Journal of Clinical Endocrinology & Metabolism 91, 3598-3602 (2006).
36. Takasu, T. et al. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. Biol. Pharm. Bull. 40, 675-680 (2017).
37. Terawaki, K. et al. New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. AJP: Endocrinology and Metabolism 306, E373-E387 (2014).